Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes

Baggiolini, Marco; Mauderli, P.; Näf, Ulrich; Catanese, B

doi:10.1007/bf01982871

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most detailed study is that of Baggiolini et al who found inhibition of the oxidative burst under some conditions (Table 3) [44]. The maximal concentrations used to examine the effects ofbenzydamine on superoxide production by neutrophils was only 30 ~tmol/L; higher than those attained in plasma after oral dosage but lower than expected in oral tissues after local application and much lower than within the mouth.…”

Section: Respiratory Burst Of Neutrophils Monocytes and Macrophagesmentioning

confidence: 98%

“…Benzydamine decreases the release of specific granules of human neutrophils stimulated with phorbol myristate acetate, PMA, or calcium ionophore, A23187, with a strong inhibition seen at 30 lxmol/L [44]. Benzydamine also inhibits azurophil granule release when neutrophils are treated with cytochalasin B and stimulated with N-formyl-methionyl-leucyl-phenylalanine, fMLP [19,44].…”

Section: Granule Releasementioning

confidence: 99%

“…At 3-30 ~tmol/L, benzydamine also inhibits the release of specific and azurophil granules from neutrophils [44].…”

Section: Respiratory Burst Of Neutrophils Monocytes and Macrophagesmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacology of benzydamine

Quane

Graham

Ziegler³

1998

Inflammopharmacol

View full text Add to dashboard Cite

Benzydamine is a topical anti-inflammatory drug which is widely available and used topically for the treatment of the mouth. It is also used as a gel for application to inflamed joints. It has physicochemical properties and pharmacological activities which differ markedly from those of the aspirin-line non-steroidal anti-inflammatory drugs. Benzydamine is a weak base unlike the aspirin-like drugs which are acids or metabolized to acids. A major contrast with the aspirin-like drugs is that benzydamine is a weak inhibitor of the synthesis of prostaglandins but it has several properties which may contribute to its anti-inflammatory activity. These properties include inhibition of the synthesis of the inflammatory cytokine, tumour necrosis factor-alpha (EC(50), 25 micromol/L). Inhibition of the oxidative burst of neutrophils occurs under some conditions at concentrations of 30 to 100 micromol/L, concentrations which may be produced within oral tissues after local application. A further activity of benzydamine is a general activity known as membrane stabilization which is demonstrated by several actions including inhibition of granule release from neutrophils at concentrations ranging from 3 to 30 micromol/L and stabilization of lysosomes. Lack of knowledge of the tissue concentrations of benzydamine limit the correlation between pharmacological activities in vitro and in vivo. The concentration of benzydamine in the mouthwash is 4 mmol/L but the concentrations in oral tissues have not been studied adequately. Limited data in the rat indicates that concentrations of benzydamine in oral tissues are approximately 100 micromol/L.

show abstract

Section: Respiratory Burst Of Neutrophils Monocytes and Macrophagesmentioning

confidence: 98%

Section: Granule Releasementioning

confidence: 99%

See 1 more Smart Citation

Pharmacology of benzydamine

Quane

Graham

Ziegler³

1998

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…4 At lower concentrations (3-30 μmol/L), this drug is also able to inhibit leukocyte-endothelial interactions, while at concentration of 10-100 μmol/L, benzydamine HCl may stabilize the mucosal membrane by virtue of its general high affinity for membranes, and may inhibit the release of azurophilic granules from neutrophils, rich in serine proteases, further contributing to its anti-inflammatory effects. 1,5 Benzydamine HCl also reduces the histamine-induced vasodilation and vascular permeability. 6 Benzydamine HCl shows antithrombotic activity 7 and the inhibition of the collagen-induced aggregation appears to be rather selective vs. other NSAIDs.…”

Section: The Mechanisms Of Action Of Benzydamine Hclmentioning

confidence: 99%

Benzydamine hydrochloride: an overview on a well-established drug with news in mechanisms of action

Ferrer-Montiel

2024

F1000Res

View full text Add to dashboard Cite

Pain and inflammation are the consequences of sore throat, dental and oral procedures, infections, ulcers and head and neck chemotherapy/radiotherapy, and their management is of fundamental importance to avoid distress in patients. Benzydamine hydrochloride (HCl) is a topical indolic nonsteroidal anti-inflammatory drug, endowed with analgesic and anesthetic activity, and with antimicrobial (including both gram-positive and gram-negative bacteria) and antifungal properties (targeting Candida albicans and non-albicans strains), used in odontostomatology, otorhinolaryngology, and gynecology for its properties. This molecule has a lipophilic nature, showing high affinity with cell membranes and exhibiting membrane stabilization properties, resulting in local anesthesia, an effect related also to the interaction of the drug with cationic channels. In addition, benzydamine HCl is able to inhibit the production of pro-inflammatory cytokines, with consequent analgesia. Moreover, benzydamine HCl is able to inhibit leukocyte-endothelial interactions and platelet aggregation. Unlike other non-steroidal anti-inflammatory drugs, benzydamine HCl does not inhibit cyclooxygenase or lipoxygenase. Here we review the most updated clinical data available on benzydamine HCl local application as spray, mouthwash or gargling and evidence of its effectiveness in inflammatory and/or septic conditions in the otorhinolaryngology and odontostomatology settings, with particular reference to sore throat, oral inflammation, dental plaque, tonsillitis/tonsillectomy and chemo- or radiotherapy-induced oral mucositis. Novel formulations for oral administration of benzydamine HCl are also reviewed, including in situ gelling formulations to be sprayed onto the damaged oral mucosa. Finally, novel data on the potential role of benzydamine HCl in nociceptor excitability are introduced.

show abstract

Independent Regulation of Leukotriene B4-Elicited Polymorphonuclear Leukocyte Exocytosis and Superoxide Generation by a Serum Factor

Mandell

1987

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Serum from a patient with inactive systemic lupus erythematosus (SLE) and ibuprofen-induced transient neutropenia was used as a probe to define further the control of human polymorphonuclear leukocyte (PMN) exocytosis and superoxide (O2-) generation. Thirty-minute preincubation of normal PMNs with 10-50% v/v of this serum, followed by washing, produced a specific dose-related suppression of leukotriene B4 (LTB4)-elicited beta-glucuronidase and lysozyme release of up to 45% and 30% respectively. If cells were not washed, the inhibition increased to 60% and 40%. Superoxide production stimulated by LTB4 was unaffected. The serum had no effect on formyl-met-leu-phe (FMLP) or phorbol myristate acetate-stimulated O2- or exocytosis. O2- and beta-glucuronidase release elicited by zymosan-treated serum (ZTS) were both decreased by 15%, but there was no increased inhibition seen if cells were not washed, or if the time of preincubation was increased from 7 to 30 min. In contradistinction, the serum inhibition of LTB4 exocytosis did show time dependence. Serum obtained when the patient was not leukopenic and sera from 6 normal controls, 2 patients with inactive SLE, 1 patient with SLE and chronic leukopenia, and 2 controls taking ibuprofen did not influence any PMN function. The serum inhibition of ZTS-induced functions was qualitatively similar to that observed when PMNs were preincubated and desensitized with ZTS in vitro. Selective inhibition of LTB4 exocytosis was not seen when PMNs were desensitized with LTB4 in vitro. These observations indicate that LTB4-elicited O2- and exocytosis can be independently and specifically regulated. The cellular site at which this serum factor acts is not clear, but the current studies strongly suggest that this inhibition is not due to in vitro deactivation by LTB4 activity.

show abstract

Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes

Cited by 6 publications

References 15 publications

Pharmacology of benzydamine

Pharmacology of benzydamine

Benzydamine hydrochloride: an overview on a well-established drug with news in mechanisms of action

Independent Regulation of Leukotriene B4-Elicited Polymorphonuclear Leukocyte Exocytosis and Superoxide Generation by a Serum Factor

Contact Info

Product

Resources

About